Overview
- Legal name
- FYR DIAGNOSTICS INC
- Registered location
- MISSOULA, MT, USA
- Website
- Company website ↗
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- Latest award activity
- Sep 3, 2026
Read company summary
FYR DIAGNOSTICS INC is associated with UEI FXC2KX47NS48 and CAGE 8KXG5 in public federal records. AcornBids currently links 1 prime award totaling $299.8K in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as Research and Development in Biotechnology (except Nanobiotechnology). These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)). Its public SAM.gov registration lists MISSOULA, MT, USA.
At a glance
Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Sep 27, 2026. Refresh pending; these totals may be out of date.
Business information
Public SAM.gov registration details.
- Legal name
- FYR DIAGNOSTICS INC
- UEI
- FXC2KX47NS48
- CAGE
- 8KXG5
- Registered address
- 1121 E BROADWAY ST, MISSOULA, MT, 59802, USA
- Registration status
- Active
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- SAM activation
- Apr 28, 2026
- Initial registration
- Apr 24, 2020
- Entity start
- Mar 31, 2020
- SAM updated
- Apr 28, 2026
- Registration expires
- Apr 24, 2027
- Fiscal year end
- Dec 31
- Place of incorporation
- DE, USA
Federal award analysis
Net transaction obligations by federal fiscal period.
Transaction history is not available in the loaded data. Annual funding is not estimated from current award totals.
Recent federal awards
Prime contract awards. Select an award to review its history and source evidence.
| Award / description | Awarding agency | Obligations | Start date | End date |
|---|---|---|---|---|
| 75N91025C00044TUMOR-DERIVED EXTRACELLULAR VESICLES FOR DIAGNOSIS OF EARLY-STAGE OVARIAN CANCER | Department of Health and Human Services | $299.8K | Sep 15, 2025 | Sep 14, 2026 |
Registration, certifications & contacts
| Registration evidence | Date |
|---|---|
| SAM updated | Apr 28, 2026 |
| Source loaded | Sep 26, 2026 |
| Initial registration | Apr 24, 2020 |
| Entity start | Mar 31, 2020 |
Registration classifications: Small Business. These are separate from the reported certificates above.
| Industry | Reported size status |
|---|---|
| 541714 — Research and Development in Biotechnology (except Nanobiotechnology) | Not reported |
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| SARJUBHAI A PATEL | Government business | Contact method not published | SAM registration | Not available |
| SARJUBHAI A PATEL | Electronic business | Contact method not published | SAM registration | Not available |
Registered industries
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source
Related companies worth researching
Explore the customer, work and award-size evidence behind each match.
Data coverage and methodology
Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.
No official subaward rows are loaded, so Acorn does not claim known teaming relationships.
Recently viewed companies
Keep your research moving
Save this company, track changes, and evaluate upcoming work against your targets.
Save to my research Find my fit